Abdelmawla, N. & Mitchell, A. J. (2006) Sudden cardiac death and antipsychotic drugs. Part 2: Monitoring and prevention. Advances in Psychiatric Treatment, 12, in press.
Adolfsson, R. & Lindblom, Y. (2002) Cardiac conduction disturbances in two patients receiving ziprasidone mono-therapy. Schizophrenia Research, 53(3) (suppl.), 162.
Al-Khatib, S. M., LaPointe, N. M., Kramer, J. M.
et al (2003) What clinicians should know about the QT interval. JAMA, 289, 2140–2127.
Allebeck, P. & Wistedt, B. (1986) Mortality in schizophrenia. A ten year follow-up based on the Stockholm County inpatient register. Archives of General Psychiatry, 43, 650–653.
Botstein, P. (1993) Is QT interval prolongation harmful? A regulatory perspective. American Journal of Cardiology, 72, 50B–52B.
Brown, S., Barraclough, B. & Inskip, H. (2000) Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212–217.
Buckley, N. A., Whyte, I. M. & Dawson, A. H. (1995) Cardio-toxicity more common in thioridazine overdose than with other neuroleptics. Journal of Toxicology. Clinical Toxicology, 33, 199–204.
Capel, M. M., Colbridge, M. G. & Henry, J. A. (2000) Overdose profiles of new antipsychotic agents. International Journal of Neuropsychopharmacology, 3, 51–54.
Cavero, I., Mestre, M., Guillon, J. M.
et al (2000) Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias.
Expert Opinion in Pharmacotherapy, 1, 947–973.
Chugh, S. P., Kelly, K. L. & Titus, J. L. (2000) Sudden cardiac death with apparently normal heart. Circulation, 102, 649–654.
Citrome, L., Brook, S., Warrington, L.
et al (2004) Ziprasidone versus haloperidol for the treatment of agitation. Annals of Emergency Medicine, 44(4) (suppl.), S22.
Committee on Safety of Medicines (1990) Cardiotoxic effects of pimozide. Current Problems in Pharmacovigilance, 29, 1.
Committee on Safety of Medicines (1996) Drug-induced prolongation of the QT interval. Current Problems in Pharmacovigilance, 22, 2.
Committee on Safety of Medicines (1998) Suspension of Availability of Serdolect (Sertindole). London: Department of Health.
Committee on Safety of Medicines (1999) Suspension of availability of sertindole (Serdolect) due to reports of sudden cardiac death. Current Problems in Pharmacovigilance, 25, 1.
Connolly, M. & Kelly, C. (2005) Lifestyle and physical health in schizophrenia. Advances in Psychiatric Treatment, 11, 125–132.
Curkendall, S. M., Mo, J., Glasser, D. B.
et al (2004) Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Journal of Clinical Psychiatry, 65, 715–720.
Czekalla, J., Beasley, C.M., Dellva, M. A.
et al (2001) Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. Journal of Clinical Psychiatry, 62, 191–198.
de Bruyne, M. C., Hoes, A. W., Kors, J. A.
et al (1999) Prolonged QT interval predicts cardiac and all-cause mortality in the elderly: the Rotterdam Study. European Heart Journal, 20, 278–284.
Dershwitz, M. (2002) Droperidol: should the black box be light gray?
Journal of Clinical Anesthesia, 14, 598–603.
Dilaveris, P. E. & Stefanadis, C. I. (2005) Molecular predictors of drug-induced prolongation of the QT interval. Current Medicinal Chemistry - Cardiovascular and Hematological Agents, 3, 105–118.
Domino, K., Anderson, E., Polissar, N.
et al (1999) Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anaesthetics and Analgesia, 88, 1370–1379.
Donatini, B., LeBlaye, I. & Krupp, P. (1992) Transient cardiac pacing is insufficiently used to treat arrhythmia associated with thioridazine. Cardiology, 81, 340–341.
Drici, M. D., Wang, W. X., Liu, X.
et al (1998) Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. Journal of Clinical Psychopharmacology, 18, 477–481.
Drolet, B., Vincent, F., Rail, J.
et al (1999) Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. Journal of Pharmacology and Experimental Therapeutics, 288, 1261–1268.
DuBuske, L. M. (1999) Second-generation antihistamines: the risk of ventricular arrhythmias. Clinical Therapeutics, 21, 281–295.
Engdahl, J., Holmberg, M., Karlson, B. W.
et al (2002) The epidemiology of out-of-hospital ‘sudden’ cardiac arrest. Resuscitation, 52, 235–245.
Ganguly, R., Kotzan, J. A., Miller, L. S.
et al (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Journal of Clinical Psychiatry, 65, 1377–1388.
Glassman, A. H. & Bigger, J. T. Jr. (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry, 158, 1774–1782.
Green, L. K. (1988) Sudden death and prolonged antipsychotic drugs. American Journal of Clinical Psychiatry, 90, 501.
Hägg, S., Spigset, O., Bate, A.
et al (2001) Myocarditis related to clozapine treatment. Journal of Clinical Psychopharmacology, 21, 382–388.
Harrigan, E. P., Miceli, J. J., Anziano, R.
et al (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology, 24, 62–69.
Hennessy, S., Bilker, W. B., Knauss, J. S.
et al (2002) Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ, 325, 1070.
Hewer, W. & Rossler, W. (1997) Mortality among inpatients with functional psychiatric disorder. Fortschritte Der Neurologie, Psychiatrie, 65, 171–181.
Hoehns, J. D., Stanford, R. H., Geraets, D. R.
et al (2001) Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy, 21, 871–883.
Jackson, T., Ditmanson, L. & Phibbs, B. (1997) Torsades de pointes and low-dose oral haloperidol. Achives of Internal Medicine, 157, 2013–2015.
Jones, D. R., Macias, C., Barreira, P. J.
et al (2004) Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatric Services, 55, 1250–1257.
Jusic, N. & Lader, M. (1994) Post-mortem antipsychotic drug concentrations and unexplained deaths. British Journal of Psychiatry, 165, 787–791.
Kalsekar, I. D., Makela, E. H. & Moeller, K. E. (2003) Analysis of West Virginia Medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia. Current Therapeutic Research – Clinical and Experimental, 64, 538–550.
Kang, U. G., Kwon, J. S., Ahn, Y. M.
et al (2000) Electrocardio-graphic abnormalities in patients treated with clozapine. Journal of Clinical Psychiatry, 61, 441–446.
Kao, L. W., Kirk, M. A., Evers, S. J.
et al (2003) Droperidol, QT prolongation, and sudden death: what is the evidence?
Annals of Emergency Medicine, 41, 546–558.
Killian, J. G., Kerr, K., Lawrence, C.
et al (1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet, 354, 1841–1845.
Kopecky, S. L. & Gersh, B. J. (1987) Dilated cardiomyopathy and myocarditis: natural history, etiology, clinical manifestations, and management. Current Problems in Cardiology, 12, 569–647.
Kriwisky, M., Perry, G. Y., Tarchitsky, D.
et al (1990) Haloperidol-induced torsades de pointes. Chest, 98, 482–484.
Lane, R. E., Cowie, M. R. & Chow, A. W. C. (2005) Prediction and prevention of sudden cardiac death in heart failure. Heart, 91, 674–680.
Liberatore, M. A. & Robinson, D. S. (1984) Torsades de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?
Journal of Clinical Psychopharmacology, 4, 143–146.
Lin, C. H., Chen, M. C., Wang, S. Y.
et al (2004) Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. Journal of the Formosan Medical Association, 103, 437–441.
Liperoti, R., Gambassi, G., Lapane, K. L.
et al (2005) Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine, 165, 696–701.
Malik, M. & Camm, A. J. (2001) Evaluation of drug-induced QT interval prolongation. Drug Safety, 24, 323–351.
Maron, B. J. (2003) Sudden death in young athletes. New England Journal of Medicine, 349, 1064–1075.
Medicines and Healthcare Products Regulatory Agency (2000) MHRA (Medicines) Restricts the Use of Thioridazine. MHRA Press Release 2000/0734. London: MHRA.
Mehtonen, O. P., Aranki, K., Malkonen, L.
et al (1991) A survey of sudden death associated with the use of antipsychotics or antidepressant drugs: 49 cases in Finland. Acta Psychiatrica Scandinavica, 84, 58–64.
Merrill, D. B., Dec, G. W. & Goff, D. C. (2005) Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology, 25, 32–41.
Modai, I, Hirschmann, S., Rava, A.
et al (2000) Sudden death in patients receiving clozapine treatment. A preliminary investigation. Journal of Clinical Psychopharmacology, 20, 325–327.
Montanez, A., Ruskin, J. N., Hebert, P. R.
et al (2004) Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. A review and qualitative overview of the prospective cohort studies. Archives of Internal Medicine, 164, 943–948.
Montout, C., Casadebaig, F., Lagnaoui, R.
et al (2002) Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophrenia Research, 57, 147–156.
Morganroth, J. (1993) Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. American Journal of Cardiology, 72, 10B–13B.
Moss, A. J. (1993) Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. American Journal of Cardiology, 72, 23B–25B.
Moss, A. J., Schwartz, P. J., Crampton, R. S.
et al (1991) The long QT syndrome: prospective longitudinal study of 328 families. Circulation, 84, 1136–1144.
Myerberg, R. J. (1997) Cardiac arrest and sudden cardiac death. In Heart Disease: A Text Book of Cardiovascular Medicine (ed. Braunwald, E.) pp. 742–779. New York: WB Saunders.
National Alliance for the Mentally Ill (1998) Cries of Anguish: A Summary of Reports of Restraints and Seclusions Abuse Received Since the October 1998 Investigation by the Hartford Courant. Arlington, VA: National Alliance on Mental Illness. http://www.nami.org/update/hartford.html
National Institute for Clinical Excellence (2004) The Short-term Management of Disturbed (Violent) Behaviour in Adult Psychiatric Inpatient Settings. First Consultation document. London: NICE.
Nose, M., Barbui, C. & Tansella, M. (2003) How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine, 33, 1149–1160.
Obias-Manno, D. & Wijetunga, M. (2004) Risk stratification and primary prevention of sudden cardiac death. AACN Clinical Issues, 15, 404–418.
O'Brien, P. & Oyebode, F (2003) Psychotropic medication and the heart. Advances in Psychiatric Treatment, 9, 414–423.
Ogata, N. & Narahashi, T. (1989) Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes. British Journal of Pharmacology, 97, 905–913.
Ösby, U., Correia, N., Brandt, L.
et al (2000) Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophrenia Research, 45, 21–28.
Priori, S. G., Alliot, E., Blomstrom-Lundqvit, C.
et al (2001) Task Force on Sudden Cardiac Death of the European Society of Cardiology. European Heart Journal, 22, 1374–1450.
Rautaharju, P. M. & Zhang, Z. M. (2002) Linearly scaled, rate-invariant normal limits for QT interval: eight decades of incorrect application of power functions. Journal of Cardiovascular Electrophysiology, 12, 1211–1218.
Ray, W. A., Meredith, S., Thapa, P. B.
et al (2001) Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry, 58, 1161–1167.
Reilly, J.G., Ayis, S. A., Ferrier, I. N.
et al (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet, 355, 1048–1052.
Reilly, J. G., Ayis, S. A., Ferrier, I. N.
et al (2002) Thioridazine and sudden unexplained death in psychiatric in-patients. British Journal of Psychiatry, 180, 515–522.
Reinert, R. E. & Hermann, C. G. (1960) Unexplained deaths during chlorpromazine therapy. Journal of Nervous and Mental Disease, 131, 435–442.
Royal College of Psychiatrists (1997) The Association between Antipsychotic Drugs and Sudden Death. Report of the Working Group of the Royal College of Psychiatrists' Psychopharmacology Sub-Group (Council Report CR57). London: Royal College of Psychiatrists.
Sadanaga, T., Sadanaga, F., Yao, H.
et al (2004) Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: Significance of bradycardia-dependent QT prolongation. Journal of Electrocardiology, 37, 267–273.
Saz, P. & Dewey, M. E. (2001) Depression, depressive symptoms and mortality in persons aged 65 and over living in the community: a systematic review of the literature. International Journal of Geriatric Psychiatry, 16, 622–630.
Spector, P. S. (2005) Diagnosis and management of sudden cardiac death. Heart, 91, 408–413.
Strachan, E. M., Kelly, C. A. & Bateman, D. N. (2004) Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning. European Journal of Clinical Pharmacology, 60, 541–545.
Straus, S. M. J. M., Bleumink, G. S., Dieleman, J. P.
et al (2004) Antipsychotics and the risk of sudden cardiac death. Archives of Internal Medicine, 164, 1293–1297.
Studenik, C., Lemmens-Gruber, R. & Heistracher, P. (1998) Pro-arrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea pig Purkinje fibres. European Journal of Pharmacological Sciences, 7, 113–118.
Suessbrich, H., Schonherr, R., Heinemann, S. H.
et al (1997) The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. British Journal of Pharmacology, 120, 968–974.
Taylor, D. M. (2003) Antipsychotics and QT prolongation. Acta Psychiatrica Scandinavia, 107, 85–95.
Titier, K., Canal, M., Deridet, E.
et al (2004) Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicology and Applied Pharmacology, 199, 52–60.
Titier, K., Girodet, P. O., Verdoux, H.
et al (2005) Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death. Drug Safety, 28, 35–51.
TREC Collaborative Group (2003) Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ, 327, 708–711.
Trenton, A. J., Currier, G. W. & Zwemer, F. L. (2003) Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs, 17, 307–324.
Waddington, J. L., Youssef, H. A. & Kinsella, A. (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10–year prospective study. British Journal of Psychiatry, 173, 325–329.
Warner, J. P., Barnes, T. R. E. & Henry, J. A. (1996) Electro-cardiographic changes in patients receiving neuroleptic medication. Acta Psychiatrica Scandinavica, 93, 311–313.
Welch, R. & Chue, P. (2000) Antipsychotic agents and QT changes. Journal of Psychiatry and Neuroscience, 25, 154–160.
Witchel, H. J. & Hancox, J. C. (2000) Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clinical Experimental Pharmacology and Physiology
Zarate, C. A., Baldessarini, R. J., Siegel, A. J.
et al (1997) Risperidone in the elderly: a pharmacoepidemiologic study. Journal of Clinical Psychiatry, 58, 311–317.
Zareba, W. & Moss, A. J. (2003) QT interval and its drug-induced prolongation. In Cardiac Repolarization: Bridging Basic and Clinical Science (eds Gussak, I., Antzelevitch, C., Hammill, S. C.
et al), pp. 311–328. Totowa, NJ: Humana Press.